title: [Hormones and venous system].
abstract: Sex hormones have an effect on venous "content" and "container" according to their chemical nature, their dosage and their mode of administration: 17 beta-estradiol (endogenous): protective effect; synthetic estrogens, at normal or low doses: thrombogenic; oral natural estrogens: thrombogenic; extra-digestive natural estrogens: non thrombogenic; non steroid progestagens (androgenic): thrombogenic; non androgenic progestagens: non thrombogenic. Clinically, the venous disease si characterized by sudden episodes occurring at key-periods of the hormonal life: puberty, pregnancy, menopause, oral contraceptives intake, substitute treatments of menopause, premenstrual syndrome. Evaluation of these different situations shows that an early treatment is possible and needed, which, although not providing a new venous wall for these constitutionally fragile patients, may act effectively at two levels: 1) correction of the haemodynamic disorder (venous reflux in the saphenous arches and the perforators; 2) resorption of tissue infiltration. As primary prevention, in a patient with hormonal disorders or who must be treated with estrogens or progestagens, the objective of our treatment is to protect the venous wall and encourage the return circulation. One must: 1) reinforce the vaso-constrictive effect and the parietal tone, 2) limit collagen and elastin alteration, 3) reinforce capillary permeability and decrease the interstitial edema, 4) normalize the haemorheological constants, 5) restore the balance hemostasis-fibrinolysis. The opinion of a phlebologist seems essential before prescribing a hormonal treatment and monitoring the effects of the treatment. Cooperation between gynaecologists and phlebologists is particularly essential in the interpretation of the clinical disorders as well as discussing the venous risk, the dosage and the administration route of sex hormones.
authors.affiliation: Service de Médecine Interne, Hôpital Tenon, Paris.
authors.forename: M
authors.initials: M
authors.lastname: Cloarec
authors.forename: P
authors.initials: P
authors.lastname: Griton
authors.forename: P
authors.initials: P
authors.lastname: Blanchemaison
authors.forename: P
authors.initials: P
authors.lastname: Caillard
authors.forename: P
authors.initials: P
authors.lastname: Desvaux
authors.forename: J R
authors.initials: JR
authors.lastname: Dumas
authors.forename: X
authors.initials: X
authors.lastname: Mouren
authors.forename: G
authors.initials: G
authors.lastname: Koubi
authors.forename: F
authors.initials: F
authors.lastname: Kirsch
mesh_terms: D002395:Catecholamines / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000494:pharmacology* / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D011372:Progestins / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D014652:Vascular Diseases / Q000517:prevention & control; D014661:Vasoconstriction / Q000187:drug effects; D014680:Veins / Q000187:drug effects*
chemical_list: D002395:Catecholamines; D004967:Estrogens; D012739:Gonadal Steroid Hormones; D011372:Progestins
vernacular_title: Hormones et système veineux.